Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan;86(1):132-54.
doi: 10.1007/s11524-008-9328-1. Epub 2008 Nov 18.

HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002

Barbara Tempalski  1 , Spencer Lieb, Charles M Cleland, Hannah Cooper, Joanne E Brady, Samuel R Friedman
Affiliations

HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002

Barbara Tempalski et al. J Urban Health. 2009 Jan.

Abstract

This research presents estimates of HIV prevalence rates among injection drug users (IDUs) in large US metropolitan statistical areas (MSAs) during 1992-2002. Trend data on HIV prevalence rates in geographic areas over time are important for research on determinants of changes in HIV among IDUs. Such data also provide a foundation for the design and implementation of structural interventions for preventing the spread of HIV among IDUs. Our estimates of HIV prevalence rates among IDUs in 96 US MSAs during 1992-2002 are derived from four independent sets of data: (1) research-based HIV prevalence rate estimates; (2) Centers for Disease Control and Prevention Voluntary HIV Counseling and Testing data (CDC CTS); (3) data on the number of people living with AIDS compiled by the CDC (PLWAs); and (4) estimates of HIV prevalence in the US. From these, we calculated two independent sets of estimates: (1) calculating CTS-based Method (CBM) using regression adjustments to CDC CTS; and (2) calculating the PLWA-based Method (PBM) by taking the ratio of the number of injectors living with HIV to the numbers of injectors living in the MSA. We take the mean of CBM and PBM to calculate over all HIV prevalence rates for 1992-2002. We evaluated trends in IDU HIV prevalence rates by calculating estimated annual percentage changes (EAPCs) for each MSA. During 1992-2002, HIV prevalence rates declined in 85 (88.5%) of the 96 MSAs, with EAPCs ranging from -12.9% to -2.1% (mean EAPC=-6.5%; p<0.01). Across the 96 MSAs, collectively, the annual mean HIV prevalence rate declined from 11.2% in 1992 to 6.2 in 2002 (EAPC, -6.4%; p<0.01). Similarly, the median HIV prevalence rate declined from 8.1% to 4.4% (EAPC, -6.5%; p<0.01). The maximum HIV prevalence rate across the 11 years declined from 43.5% to 22.8% (EAPC, -6.7%; p<0.01). Declining HIV prevalence rates may reflect high continuing mortality among infected IDUs, as well as primary HIV prevention for non-infected IDUs and self-protection efforts by them. These results warrant further research into the population dynamics of disease progression, access to health services, and the effects of HIV prevention interventions for IDUs.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Estimated annual percent change (SEER) in IDU HIV prevalence rates from 1992–2002.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. None
    2. Brown BS, Beschner GM. Handbook on Risk of AIDS: Injection Drug Users and Sexual Partners. Westport, CT: Greenwood; 1993.
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '7572963', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/7572963/'}]}
    2. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neaigus A. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high- and low-seroprevalence cities. Am J Epidemiol. 1995;142:864–874. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0140-6736(96)11380-5', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0140-6736(96)11380-5'}, {'type': 'PubMed', 'value': '9269214', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9269214/'}]}
    2. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programs for prevention of HIV infection. Lancet. 1997;21:1797–800. doi:10.1016/S0140-6736(96)11380-5. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2105/AJPH.88.1.108', 'is_inner': False, 'url': 'https://doi.org/10.2105/ajph.88.1.108'}, {'type': 'PMC', 'value': 'PMC1508387', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1508387/'}, {'type': 'PubMed', 'value': '9584014', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/9584014/'}]}
    2. Kral AH, Bluthenthal RN, Booth RE, Watters JK. HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities. Am J Public Health. 1998;88:108–113. - PMC - PubMed
    1. None
    2. Malliori M, Zunzunegui MV, Rodriguez-Arenas A, Goldberg D. Drug injecting and HIV-1 infection: major findings from a multi-city study. In: Stimson GV, Des Jarlais DC, Ball A, eds. Drug Injecting and HIV Infection: Global Dimensions and Local Responses. London: Taylor and Francis; 1998.

Publication types

MeSH terms